New Breast Cancer cases annually is at one million patients world wide. Of which 170,000 are TNBC. The trials so far I believe, has some Hers and Hers2 patients included. Correct me if I am wrong about the Hers & Hers2 being included. Maybe those results go to the basket trial?

Potential revenue on a million patients is 60 billion annually at $60,000/year Leronlimab therapy. Not that Leronlimab would take over the whole breast cancer market but I would assume a great share of it.

Breast cancer is one of 23 cancer indications and when you start tallying up all indications annually just how much would cancer be worth? I viewed a trend graph on Naders wall a few month ago in a proactive video stating cancer was 121 billion potential. I am thinking that number is an annual revenue possible prediction for all indications and not just Leronlimab’s market share. It’s a pretty big pool to be swimming in. Wonder what an annual 80-100 billion revenue would do for the SP? Considering it is an annual reported cancer patient amount. It doubles the second year and compounds by the same annual amount yearly. Say first year is 80 Billion then 2nd year it’s 160 billion then 3rd year 240 billion and so forth and so on. All this is possible when the patients never die anymore and need Leronlimab to not progress any cancer.

Could these numbers be possible or real? What would the stock price be at 5 years and 400 billion annual revenue? Can anyone put a stock price on that revenue? Can someone put a real stock price number to $400,000,000,000. Is this where Nader thinks we achieve a high triple digit stock price? Maybe quadruple digit stock price? This is just cancer...